Compendium

Pharmaceutical Process Engineering — Engineering Reference

27 min read

Pharmaceutical Process Engineering — Engineering Reference

1. At a glance

Pharmaceutical manufacturing spans drug substance (DS / API) synthesis through drug product (DP) formulation, fill-finish, packaging, and temperature-controlled distribution, all executed under the strictest manufacturing regulatory regime on Earth: current Good Manufacturing Practice (cGMP). Three primary modalities now coexist in a single industrial ecosystem:

  • Small-molecule — organic-chemistry synthesis at kg-to-tonne scale; oral solid dosage (tablets, capsules) still dominates global Rx volume by units. Examples: atorvastatin (Lipitor, Pfizer), sitagliptin (Januvia, Merck), apixaban (Eliquis, BMS/Pfizer), nirmatrelvir/ritonavir (Paxlovid, Pfizer).
  • Biologics — recombinant proteins, monoclonal antibodies (mAbs), fusion proteins, vaccines, blood-derived products. Produced from living cells (CHO, E. coli, yeast, insect, HEK293). Examples: adalimumab (Humira, AbbVie), pembrolizumab (Keytruda, Merck), dupilumab (Dupixent, Regeneron/Sanofi).
  • Advanced therapies (ATMPs) — autologous + allogeneic cell therapy, gene therapy, mRNA, oligonucleotide, lipid nanoparticle (LNP)-delivered. Examples: tisagenlecleucel (Kymriah, Novartis), onasemnogene abeparvovec (Zolgensma, Novartis), exa-cel (Casgevy, Vertex/CRISPR Therapeutics, 2023 approval), tozinameran (Comirnaty, Pfizer/BioNTech).

2024-26 industry trends:

  1. GLP-1 supply scale-up — semaglutide (Wegovy/Ozempic, Novo Nordisk) + tirzepatide (Zepbound/Mounjaro, Eli Lilly) demand has driven the largest pharmaceutical capex wave in a generation: Lilly 13 B+ committed (Denmark, Catalent acquisition).
  2. Continuous manufacturing (CM) adoption — FDA + EMA actively encouraging since 2015; now ~12 commercial-CM oral-solid products approved (Janssen, Vertex, Eli Lilly, Pfizer).
  3. Advanced therapies — six CAR-T products on US market, three sickle-cell gene therapies (Casgevy, Lyfgenia), AAV products for DMD (Elevidys, Sarepta 2023), hemophilia (Hemgenix, CSL 2022; Roctavian, BioMarin 2023).
  4. AI/ML-driven discovery operations — Insitro, Recursion (NYSE:RXRX), Isomorphic Labs (Alphabet), Schrödinger; “AI-discovered” molecules entering Phase II/III (Insilico, BenevolentAI, Exscientia/Sumitomo).

SI units are primary throughout; product names use the originator + year of approval; standards reference the issuing body + most recent revision.

2. Drug development lifecycle

Average modern timeline: ~10-15 years from lead identification to approval. Fully-loaded capitalised cost (Tufts CSDD 2020 update): **2.87 B; cell + gene therapies trend higher ($3-5 B).

StageDuration (typical)Subjects / scaleOutput
Discovery2-4 yrIn silico + biochem assaysLead compound, IP
Preclinical1-2 yrCell + animal (rodent + non-rodent)IND (US) / CTA (EU) filing
Phase I1-2 yr20-100 healthy or patient subjectsSafety, PK/PD, MTD
Phase II2-3 yr100-300 patientsEfficacy signal, dose-ranging
Phase III3-5 yr1000-5000+ patients, multi-sitePivotal efficacy + safety
NDA / BLA / MAA6-18 mo review—Approval (FDA NDA/BLA, EMA MAA)
Phase IVindefinitepost-marketPharmacovigilance, label expansion

Accelerated regulatory tracks compress this: Breakthrough Therapy, Fast Track, Accelerated Approval, Regenerative Medicine Advanced Therapy (RMAT) (FDA); PRIME, Conditional Marketing Authorisation (EMA); Sakigake (PMDA Japan). RMAT designation is meaningful for CAR-T + gene therapy and shortens AT review timelines materially.

Filing types (US):

  • IND (Investigational New Drug) — to begin clinical trials.
  • NDA (New Drug Application) — small-molecule, 505(b)(1) full or 505(b)(2) hybrid.
  • BLA (Biologics License Application) — biologics under FDA CBER or CDER.
  • ANDA (Abbreviated NDA) — generic, demonstrates bioequivalence.
  • 351(k) — biosimilar pathway (BPCIA 2009).
  • Priority Review Voucher (PRV) — granted for tropical / pediatric rare / medical countermeasure approvals; tradeable, recent sales $80-110 M.

3. Small-molecule API synthesis

3.1 Route scouting + selection

Process chemistry evaluates candidate synthetic routes on five axes: overall yield, cost of goods (CoG), scalability (heat / mass transfer, mixing), impurity profile (ICH Q3A/B/C/D limits), safety + environmental footprint (PMI process mass intensity, E-factor, Sheldon 1992). Modern targets: PMI < 100 kg/kg for API, E-factor < 50 for fine-chem; green-chemistry adoption (Anastas + Warner principles 1998) driving solvent recovery + biocatalysis (Codexis evolved enzymes — sitagliptin transaminase, Merck 2010).

3.2 Reactor + equipment

  • Batch reactors — jacketed stainless 316L (most common), glass-lined steel (Pfaudler, De Dietrich, Buss-SMS-Canzler) for corrosive chemistry, Hastelloy C-276 / B-3 for chloride / strong acid, Inconel for high-T high-P hydrogenations. Typical sizes 50 L (pilot) → 1000 L → 6300 L → 16 000 L (commercial).
  • Hydrogenation — Parr / Buchi for lab + pilot; full-scale at Lonza Visp, Cambrex Karlskoga, Albemarle.
  • Solid-handling — Nutsche filter-dryers (Rosenmund-Mahr, 3V Tech, Comber), agitated filter-dryers, conical screw dryers.
  • Crystallisation — cooling (linear / cubic / antisolvent-modulated), antisolvent (water added to organic), evaporative, reactive. Crystal-form control (polymorph screen) is regulatory-critical (cf. ritonavir Form II 1998 Norvir crisis — Abbott reformulation).
  • Drying — vacuum tray, conical, spray (Niro/GEA), spin-flash, freeze (Steris LyoStar, IMA Telstar, GEA).

3.3 Reaction monitoring + PAT in API

In-line FTIR (Mettler-Toledo ReactIR + iC IR software), in-line Raman (Kaiser RamanRxn2/RxnRxn, now Endress+Hauser; Resolution Spectra Systems), in-line NIR (Bruker Optics Matrix-F, Sentronic). Off-line HPLC, UPLC (Waters Acquity), GC, NMR (Bruker Fourier 80, Magritek Spinsolve benchtop). Multivariate analysis: Sartorius SIMCA, Aspen ProMV. Real-time end-point detection enables batch-to-batch tightening and is foundational for QbD + RTRT.

3.4 Continuous-flow chemistry

Continuous-flow (microreactor + meso-reactor) advantages: 100-1000× better surface-to-volume ratio (heat transfer), small reactor inventory (intrinsically safer for energetic / azide / diazomethane chemistry), rapid mixing, telescoped multi-step. Equipment vendors: Corning Advanced-Flow Reactors (AFR) glass / SiC plates, Vapourtec R-series, Chemtrix Plantrix, Syrris Asia/Africa, ThalesNano H-Cube (continuous hydrogenation), Ehrfeld (Bayer / Lonza). Production adopters: Lonza (Visp continuous-flow plant), Snapdragon Chemistry (Cambridge MA, acquired by Cambrex 2022), Pfizer (Groton portable on-demand), Janssen (Beerse). DARPA + DARPA-Battelle “Pharmacy-on-Demand” portable units demonstrated.

4. Biologic API manufacturing — upstream

4.1 Cell-line development

Host cellUseTypical titer (mAb)
CHO (Chinese Hamster Ovary)mAb, Fc fusion, recombinant proteins5-10 g/L (fed-batch)
HEK293AAV, lentivirus, some recombinant1e11-1e15 vg/L (AAV)
Sf9 / Sf21 (insect)baculovirus VLP, Spark-AAV1e10-1e12 vg/L
PER.C6 (Crucell/J&J)adenovirus, mAbsimilar to CHO
E. coliinsulin, GCSF, peptides1-10 g/L (inclusion bodies)
Pichia pastorisenzymes, hormones1-30 g/L

Cell-line generation: transfection (lipid, electroporation), selection (DHFR/MTX amplification, GS-knockout with methionine sulfoximine, glutamine-synthetase-Lonza), single-cell cloning (limiting dilution, Berkeley Lights Beacon, Cytena, Solentim VIPS), monoclonality documentation per ICH Q5A/Q5B/Q5D. Master Cell Bank (MCB) → Working Cell Bank (WCB) under cGMP; characterisation per ICH Q5D includes identity, viability, genetic stability, adventitious agent freedom.

4.2 Bioreactor scale-up

Typical seed-train + production train: vial thaw → shake flask → 2 L wave bag → 50 L → 200 L → 1000 L → 2000 L SUB (single-use bioreactor) or 5000-25 000 L stainless for legacy commercial mAb.

Single-use (SUS) dominates ≤2000 L: lower capex, faster turnaround, no cleaning validation, smaller QC burden. Stainless still preferred ≥10 000 L (commodity mAbs, biosimilars) or for very-long campaigns.

Vendors:

  • Thermo Fisher HyPerforma (formerly Hyclone) SUB 50/100/250/500/1000/2000 L.
  • Sartorius BIOSTAT STR 50-2000 L.
  • Cytiva (GE) Xcellerex XDR 50-2000 L; ReadyToProcess consumables.
  • Merck Mobius 50-2000 L.
  • Pall iCellis for adherent (AAV, vaccine).
  • ABEC Custom Single Use (CSU) up to 6000 L (largest SUB).

4.3 Process intensification

  • Fed-batch — base-load mode, typical 12-18 day duration, titers 3-10 g/L mAb.
  • Perfusion — continuous media exchange via ATF (alternating tangential flow, Repligen XCell ATF) or TFF, retains cells; steady-state operation 30-60+ days, higher volumetric productivity (1-3 g/L/day).
  • N-1 perfusion seed — high-cell-density inoculum (50-100×10⁶ cells/mL) into N-stage fed-batch — compresses seed train, increases facility throughput. Adopted at Sanofi Framingham, Boehringer Ingelheim Biberach.

4.4 Media + feed

Chemically-defined (CD) media has displaced hydrolysate / serum-containing for cGMP since ~2005-10. Vendors: Thermo Fisher Gibco, Cytiva HyClone, Sigma Cellvento, Lonza PowerCHO. Custom blends developed in DoE statistical screens (JMP, Design-Expert). Feed strategy (CHEF — concentrated half-strength enriched feed; or proprietary) added boluses 30-60% of culture volume cumulative.

4.5 In-line monitoring

  • DO (dissolved O₂) optical (Hamilton VisiFerm, Mettler-Toledo InPro 6970), pH glass / ISFET, temperature PT100.
  • Off-gas mass spec (Thermo Prima BT, Hamilton OGM).
  • Viable-cell density (VCD) — capacitance (Aber Instruments / Bug Lab Futura, Hamilton Incyte), dielectric spectroscopy; widely adopted for fed-batch control.
  • Raman (Kaiser RamanRxn3/4, now Endress+Hauser; Tornado Spectral) for glucose / lactate / VCD / titer in-line. Multivariate PLS models. Photonic Solutions, Real-Tech Pharma, Resolution Spectra.

5. Downstream biologic processing (DSP)

Sequence: harvest → capture → polish 1 → polish 2 → viral inactivation + filtration → UF/DF → bulk DS.

5.1 Harvest + clarification

  • Disk-stack centrifuge (GEA Westfalia, Alfa Laval Culturefuge / Brew/PharmaSep) for large stainless, or
  • Depth filtration alone (Millipore Millistak+, Sartorius Sartoclear, 3M Zeta Plus) common for SUB ≤2000 L.

5.2 Capture chromatography

For mAb: Protein A affinity is universal. Cytiva MabSelect SuRe / PrismA, Tosoh Toyopearl AF-rProtein A, Purolite Praesto Jetted A50, Repligen ATOLL. Loading 30-70 g mAb / L resin, residence time 4-6 min, low-pH elution (pH 3.5).

Pre-packed columns (Cytiva ReadyToProcess, Repligen OPUS) eliminate column packing for clinical + commercial small-batch.

5.3 Polish

Two orthogonal chromatographies typically follow:

  • Cation exchange (CEX) — bind-elute for charge-variant control (Cytiva Capto S ImpAct, Tosoh SP-650M).
  • Anion exchange (AEX) — flow-through for HCP / DNA / endotoxin removal (Cytiva Capto Q ImpRes, Sartorius STIC PA Q membrane).
  • Multimodal — Capto adhere, Capto MMC, Tosoh ToyoScreen MX.

Membrane chromatography (Sartobind, Cytiva ReadyToProcess Q, Repligen Mustang) for low-binding flow-through impurity removal in continuous mode.

5.4 Viral safety

ICH Q5A(R2) revised 2024:

  • Viral inactivation — low-pH hold (pH 3.5, 60 min), solvent-detergent (Triton X-100 phased out 2023 EU REACH; replaced by Triton-X-100R, Polysorbate-80 + tri-n-butyl phosphate).
  • Viral filtration — 20 nm parvovirus filters (Asahi Planova 20N, Pall Pegasus, Sartorius Virosart, Merck Viresolve Pro).

5.5 UF/DF (TFF)

Tangential Flow Filtration with 30 kDa / 50 kDa / 100 kDa MWCO cassettes; concentrate then diafilter into formulation buffer. Equipment: Pall Cadence, Cytiva ÄKTA ReadyFlux / Process, Repligen XCell, Sartorius Sartoflow. Final DS concentration commonly 50-200 g/L (high-concentration mAb for subcutaneous routes — viscosity 1-30 mPa·s management critical).

5.6 Bulk drug substance (BDS)

Freeze ≤−20 °C or refrigerate 2-8 °C in disposable single-use bags (Sartorius Flexsafe Pro, Cytiva ReadyToProcess) or stainless bottles. Cryomace / Celsius (Sartorius) controlled-rate freeze for large-bag mAb at −40 °C.

6. Drug product fill-finish

6.1 Sterile filtration

0.22 µm sterilising-grade hydrophilic PVDF / PES membranes (Millipore Durapore, Sartorius Sartopore 2, Pall Supor EKV, Cytiva ReadyToProcess). Pre-use + post-use integrity test (bubble-point, diffusion, WIT) per ASTM F838 / PDA TR26.

6.2 Aseptic filling

Container formats: glass vials (2R, 6R, 10R, 20R — DIN ISO 8362), prefilled syringes (PFS — BD Hypak, Schott TopPac, SCHOTT iQ), cartridges (autoinjector pens for GLP-1, insulin), bags (LVP / IV).

EU GMP Annex 1 (revised August 2022, in force August 2023) is the dominant global aseptic standard. Key requirements: Contamination Control Strategy (CCS) holistic document, Grade A protected by barrier (RABS or isolator) for all open product, microbiological air quality limits, media-fill simulations.

Filling-line types:

  • Restricted Access Barrier System (RABS) — open / closed.
  • Isolator — fully enclosed, VHP-decontaminated (vapourized hydrogen peroxide), e.g. STERIS VHP ARD, Bioquell Clarus, Ortner.
  • Robotic + gloveless — Cytiva SA25 Aseptic Filling Workcell (formerly Vanrx Microcell), STÄUBLI Stericlean robots, Bausch+Stroebel custom robotic isolator.

Major fill-finish vendors: Bausch+Strobel (Syntegon B+S since 2024), OPTIMA pharma, IMA Life, Bosch (Syntegon), Groninger, SKAN AG (isolators), Cytiva.

6.3 Lyophilisation

Freeze-drying for thermolabile biologics + mRNA + some small-molecule. Equipment: GEA LYOMAX, IMA Life LYOMAX/LyoFlex, OPTIMA Pharma SyntegoN HOF, Telstar. Cycle development uses LyoStat / MicroFD (Millrock) at small scale. SMART Freeze-Dryer + TDLAS (tunable diode laser absorption spectroscopy, Physical Sciences Inc.) for in-process moisture monitoring.

6.4 Inspection + packaging

  • Automated visual inspection (AVI) — Bosch AIM 5023/5042, Eisai AIM 588, Brevetti CEA, Stevanato Group.
  • Container Closure Integrity (CCI) — high-voltage leak detection (HVLD), helium leak, headspace gas (FMS, Lighthouse Instruments).
  • Serialisation / aggregation — DSCSA (US Drug Supply Chain Security Act, fully enforced Nov 2024), EU FMD (EU Falsified Medicines Directive 2019).

6.5 Cold-chain distribution

  • Refrigerated 2-8 °C — most mAbs, insulin, vaccines (varicella, MMR refrigerated).
  • Frozen −20 °C — some mRNA (Moderna mRNA-1273 latest formulations), CAR-T DS intermediate.
  • Ultra-cold −70 °C — Pfizer/BioNTech BNT162b2 original; Cryoport liquid-nitrogen dewars for CAR-T DP shipment (−150 °C vapour-phase LN₂).
  • Validated shippers — World Courier, Marken, CSafe, Pelican BioThermal Crēdo, va-Q-tec.

7. Quality + GMP regulatory framework

7.1 cGMP (current Good Manufacturing Practice)

US (FDA):

  • 21 CFR 210 — general cGMP for drug products.
  • 21 CFR 211 — finished pharmaceuticals (oral, parenteral, topical).
  • 21 CFR 600-680 — biological products.
  • 21 CFR 1271 — HCT/Ps (human cells, tissues, cellular + tissue-based products; gene therapy cells).
  • 21 CFR Part 11 — electronic records + signatures.
  • 21 CFR 820 — Quality System Regulation (devices; relevant for combination products).

EU:

  • EudraLex Volume 4 — EU GMP guide; Part I (medicinal products), Part II (APIs, identical to ICH Q7), Part III (PQS), Part IV (ATMPs).
  • Annexes 1-22 — sterile (Annex 1, 2022 revised), biological (Annex 2), radiopharm (Annex 3), veterinary (Annex 4-5), computerised systems (Annex 11), QP certification (Annex 16), ATMP (Annex 2A).

International:

  • ICH Q7 — GMP for active pharmaceutical ingredients (2000, harmonised).
  • ICH Q9 — Quality Risk Management (R1 2023).
  • ICH Q10 — Pharmaceutical Quality System.
  • PIC/S — Pharmaceutical Inspection Co-operation Scheme; harmonised GMP for member regulators.
  • WHO TRS (Technical Report Series) annexes — global baseline for emerging-market regulators.

7.2 Validation

  • IQ / OQ / PQ — Installation / Operational / Performance Qualification for equipment + utility + facility.
  • Process Validation (PV) — FDA 2011 guidance + ICH Q8/Q11; lifecycle approach: Stage 1 design, Stage 2 PPQ (Process Performance Qualification) typically 3 consecutive successful batches at commercial scale, Stage 3 continued process verification (CPV).
  • Cleaning validation — verify residue limits, including therapeutic-dose-based + PDE (Permitted Daily Exposure) per EMA / Risk-MaPP.
  • Analytical method validation — ICH Q2(R2) 2023 update — specificity, accuracy, precision, LOD, LOQ, linearity, range, robustness.

7.3 Quality systems

  • CAPA (Corrective + Preventive Action), deviations / excursions, OOS (Out of Specification — Barr Labs 1993 ruling defines investigation expectation), OOT (Out of Trend), change control.
  • Annual Product Review (APR) / Product Quality Review (PQR).
  • Data integrity (DI) — ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, + Complete, Consistent, Enduring, Available). FDA + MHRA + WHO 2018 guidance.

8. Quality by Design (QbD) + PAT

8.1 QbD framework

ICH Q8(R2) + Q9(R1) + Q10 + Q11 + Q12 (Lifecycle Management) + Q13 (Continuous Manufacturing, 2022) + Q14 (Analytical Procedure Development, 2023).

Elements:

  • Quality Target Product Profile (QTPP) — dose, route, container, pharmacokinetics target.
  • Critical Quality Attribute (CQA) — physical, chemical, biological attribute that must be within range (purity, potency, identity, sterility, particle size, dissolution, aggregation).
  • Critical Material Attribute (CMA) — raw material property impacting CQA.
  • Critical Process Parameter (CPP) — process parameter (T, pH, residence time, agitation rate, sieve size) impacting CQA.
  • Design Space — multivariate combination of CPPs proven to deliver CQA. Operation within design space ≠ change requiring regulatory submission.
  • Control Strategy — set of controls (in-process tests, RTRT, end-product release) ensuring CQA met.
  • Risk Assessment — Ishikawa fishbone, FMEA, HACCP, ICH Q9 tools.

8.2 PAT (Process Analytical Technology)

FDA guidance 2004 — build quality in via in-line / on-line / at-line measurement + multivariate modelling + feedback control.

PAT sensor stack:

  • Near-Infrared (NIR) — Bruker MATRIX-F, Sentronic SentroPAT, Foss NIRSystems, ABB FT-NIR. Quantitative API + moisture + blend uniformity.
  • Raman — Kaiser RamanRxn3/4 (Endress+Hauser), Resolution Spectra, Tornado Spectral, IPS-Process Instruments. mAb titer in bioreactor, polymorph monitoring in crystallisation.
  • UV/Vis — chromatography on-line.
  • Imaging — Eyecon (Innopharma) for particle sizing, Malvern Mastersizer (continuous), Sympatec Helos.
  • MS — Waters Xevo TQ-XS, Thermo Q Exactive, SCIEX Triple Quad — process MS rare but appearing.
  • HPLC + UPLC — at-line.

Multivariate Data Analysis (MVDA): Sartorius SIMCA / SIMCA-online, Aspen ProMV / Mtell, Camo Analytics, JMP (SAS) — PCA, PLS, OPLS, batch evolution models.

8.3 Real-Time Release Testing (RTRT)

Final release decision made from in-process measurements rather than end-product testing. Adopted in commercial CM lines (Janssen Prezista, Vertex Trikafta). Substantial QC lab cost reduction; greater regulatory burden up-front.

9. Continuous manufacturing (CM)

FDA + EMA + PMDA aligned in encouraging CM since the 2015-2019 guidance cycle; ICH Q13 (2022) provides harmonised framework.

9.1 Commercial CM landmarks

YearProductSponsorModality
2015Prezista (darunavir)JanssenContinuous oral solid switch
2016Orkambi (lumacaftor/ivacaftor)VertexContinuous oral solid
2017Verzenio (abemaciclib)Eli LillyContinuous oral solid (de novo)
2019Symdeko / TrikaftaVertexContinuous oral solid
2022Paxlovid (nirmatrelvir/r)PfizerContinuous oral solid (pandemic scale-up)
2024Multiple J&J + Lilly + GSKvariouscontinuing expansion

9.2 CM unit operations

  • Continuous direct compression (CDC) — loss-in-weight feeders (Coperion K-Tron, Schenck Process, Gericke), continuous blender (GEA ConsiGma, Glatt GCG), tablet press (Korsch, Fette).
  • Continuous wet granulation (CWG) — twin-screw (GEA ConsiGma-25, Glatt MODCOS).
  • Continuous-flow API — Section 3.4 (flow chemistry).
  • Continuous downstream (3C, 4C) — multi-column counter-current chromatography (Cytiva BioSC, ChromaCon Contichrom, Pall Cadence BioSMB), BioContinuum integrated DSP (Merck), Sartorius Integrated Solutions.

9.3 Advantages

Smaller footprint (~20-50% of batch), faster scale-up (no separate pilot stage), tighter quality (continuous PAT + feedback), inventory + WIP reduction, lower CoG long-term. Capex similar or slightly higher but lower ongoing.

10. mRNA + LNP (post-COVID rapid commercialisation)

10.1 Drug substance (mRNA) process

  1. Linearised DNA template (plasmid expansion in E. coli, restriction-enzyme linearisation, purification).
  2. In Vitro Transcription (IVT) — T7 RNA polymerase + NTPs (including N¹-methyl-pseudouridine for nucleoside-modified mRNA per Karikó + Weissman 2005, Nobel 2023); cap analogue (Trilink CleanCap AG, m⁷G-cap) co-transcriptional or post-transcriptional vaccinia capping. Reaction in batch stirred tank or single-use bag, 1-2 hr.
  3. DNase digest (remove template).
  4. Purification — oligo-dT affinity (poly-A tail binding; Cytiva Sera Mag-derived, Sartorius), TFF, IEX or RP-HPLC for double-stranded RNA (dsRNA) impurity removal.

10.2 Drug product — LNP encapsulation

  • Microfluidic mixing — laminar coflow / staggered herringbone (Cytiva NanoAssemblr Ignite / Blaze ex Precision NanoSystems; Knauer IJM Impingement Jets Mixer).
  • Lipids — ionisable cationic (ALC-0315 Pfizer/BioNTech, SM-102 Moderna), DSPC structural, cholesterol, PEG-lipid (ALC-0159, PEG-DMG). Mole ratios ~50:10:38.5:1.5.
  • Buffer exchange + concentration — TFF.
  • Fill-finish — sterile filtration challenging due LNP size (~80-120 nm) approaches 0.22 µm cutoff; some products use redundant 0.45/0.22 µm or alternative.

10.3 Cold-chain reality

ProductOriginal tempImproved (2022+)
BNT162b2 (Comirnaty)−80 °C ± 10 °C, ≤6 months−20 °C 10 weeks; 2-8 °C 1 month
mRNA-1273 (Spikevax)−20 °C2-8 °C 30 days

LNP formulation chemistry improvements (lyophilised LNP, alternative ionisable lipids) targeting 2-8 °C stability.

10.4 mRNA ecosystem 2024-26

Commercial: Pfizer/BioNTech, Moderna. Pipeline: Sanofi (SP0273 flu), CureVac (CV0501 flu), Arcturus (lunar-COV19). CDMOs: Lonza (Visp), Catalent (Bloomington — acquired by Novo Holdings 2024 for $16.5 B to lock in Wegovy fill capacity), Thermo Fisher, Recipharm, Aldevron (Danaher — plasmid DNA).

11. Cell + gene therapy

11.1 Autologous CAR-T

Product (year)SponsorTarget
Kymriah (tisagenlecleucel, 2017)NovartisCD19 (ALL, DLBCL)
Yescarta (axicabtagene ciloleucel, 2017)Gilead/KiteCD19 (DLBCL)
Tecartus (brexucabtagene autoleucel, 2020)Gilead/KiteCD19 (MCL, ALL)
Breyanzi (lisocabtagene maraleucel, 2021)BMS/JunoCD19 (DLBCL)
Abecma (idecabtagene vicleucel, 2021)BMS/2seventy bioBCMA (MM)
Carvykti (ciltacabtagene autoleucel, 2022)J&J/LegendBCMA (MM)

Process flow:

  1. Leukapheresis — patient T-cells collected at clinic (~1-2 hr).
  2. Cold-chain shipment to mfg facility.
  3. T-cell selection (CD4/CD8, e.g. Miltenyi CliniMACS).
  4. Activation — anti-CD3/CD28 beads (Dynabeads / Thermo Fisher) or Miltenyi T Cell TransAct.
  5. Transduction — lentivirus (most CAR-T) or retrovirus encoding CAR transgene.
  6. Expansion — bioreactor (G-Rex Wilson Wolf, Xuri Cell Expansion, Miltenyi CliniMACS Prodigy, Lonza Cocoon, Cytiva Sefia).
  7. Wash + formulate + cryopreserve — controlled-rate freezer (Asymptote VIA Freeze, Planer).
  8. Quality control + release — sterility (BacT/Alert), endotoxin, mycoplasma (rapid PCR), potency (cytokine release, cytotoxicity), CAR expression (flow cytometry), VCN (vector copy number qPCR).
  9. Ship LN₂ vapor-phase → infusion at clinic.

Total vein-to-vein ~10-21 days; pricing 475 k per dose; outcomes-based agreements common.

11.2 Allogeneic + iPSC-derived

Off-the-shelf, single-donor → many patients. CRISPR / TALEN edits to ablate TCR-α + HLA + CD52 to reduce rejection. Pipeline: Allogene ALLO-501/715, Caribou CB-010, Fate Therapeutics iPSC CAR-NK, Century Therapeutics, Vor Bio.

11.3 AAV gene therapy

Product (year)SponsorIndication
Luxturna (voretigene neparvovec, 2017)Spark/RocheRPE65 retinal dystrophy
Zolgensma (onasemnogene abeparvovec, 2019)Novartis (AveXis)SMA
Hemgenix (etranacogene dezaparvovec, 2022)CSL/uniQureHemophilia B
Roctavian (valoctocogene roxaparvovec, 2023)BioMarinHemophilia A
Elevidys (delandistrogene moxeparvovec, 2023)SareptaDMD

Manufacturing:

  • Suspension HEK293 triple-plasmid transfection (cap/rep, GoI, helper) in 50-2000 L SUB; Pall iCellis + Cytiva CellSTACK adherent legacy.
  • Lysis + nuclease digest (Benzonase).
  • Capture chromatography — AAV-specific (POROS CaptureSelect AAVX, AVB Sepharose).
  • Full-empty capsid separation — analytical: AUC (analytical ultracentrifugation, Beckman ProteomeLab XL-A/I), MP (mass photometry, Refeyn TwoMP), CDMS (charge-detection MS); preparative: cesium chloride gradient (legacy), AEX gradient (Capto Q ImpRes, POROS XS).
  • TFF + sterile fill.
  • Doses 1e13-1e15 vg/kg (Zolgensma ~2.1e14 vg/kg ≈ ~1.5e16 vg per 70 kg adult).

CDMO landscape: Catalent (Maryland AAV), Lonza (Houston), WuXi Advanced Therapies, Charles River, Andelyn Biosciences, Forge Biologics (Ajinomoto 2023), Resilience, Oxford BioMedica (Boehringer 2024).

11.4 Lentivirus + retrovirus

Ex-vivo gene editing + CAR-T transduction. Manufactured in HEK293T transient transfection (3-4 plasmid: gag-pol, env-VSVG, rev, transfer); ~1e6-1e7 TU/mL crude, >1e9 TU/mL purified. Vendors: Oxford BioMedica, Lonza, Charles River, Yposkesi (SK pharmteco).

11.5 CRISPR ex-vivo

Casgevy (exagamglogene autotemcel / exa-cel, Vertex + CRISPR Therapeutics, FDA Dec 2023): autologous CD34+ HSCs edited ex vivo with CRISPR-Cas9 RNP electroporation to disrupt BCL11A erythroid enhancer, reactivating fetal haemoglobin in sickle-cell + β-thalassemia. Lyfgenia (bluebird bio, lovotibeglogene autotemcel) approved same day uses lentiviral β^A^-T87Q. Pricing Casgevy 3.1 M.

12. GLP-1 + obesity drug scale-up

12.1 Demand + capex

  • Semaglutide (Wegovy, Ozempic, Rybelsus — Novo Nordisk; first approval 2017 oral, 2021 chronic-weight-management injectable). 2023 revenue ~$21 B; 2024 capacity-constrained.
  • Tirzepatide (Mounjaro 2022, Zepbound 2023 — Eli Lilly). Dual GIP+GLP-1 agonist. 2024 revenue trajectory ~$10-13 B.

Capex commitments through 2026:

  • Eli Lilly — 3.7 B + 5 B greenfield), Limerick Ireland ($1 B), Boston MA, RTP NC.
  • Novo Nordisk — 6 B), Clayton NC (16.5 B closed 2024 — three former Catalent fill-finish sites (Bloomington IN, Brussels, Anagni IT) transferred to Novo Nordisk to lock in capacity.

12.2 Synthesis chemistry

Semaglutide + tirzepatide are 31-39 amino-acid peptides with lipidation (C18 fatty diacid via γGlu-2xOEG linker on semaglutide). Two synthesis paradigms:

  • Solid-phase peptide synthesis (SPPS) — Fmoc chemistry on Rink amide or Wang resin (Bachem, PolyPeptide, CEM Liberty Blue, Biotage SyroWave); coupling with HBTU/HATU + DIEA; cleavage with TFA cocktail.
  • Hybrid solid-liquid + recombinant — Novo Nordisk uses partial recombinant production in yeast (Saccharomyces cerevisiae) → chemical lipidation; this gives biologic-like scale economics.

CDMO support: Bachem (Switzerland, $1 B+ capex announced 2023), PolyPeptide Group (Denmark / France / Belgium / US / India), Lonza (Visp peptide). Demand for 2-chlorotrityl chloride resin, Fmoc amino acids, HBTU/HATU has surged 5-10×.

12.3 Cartridge fill + autoinjector

GLP-1 is delivered subcutaneously weekly via single-use prefilled pen (Novo FlexTouch, Lilly KwikPen-like). Cartridge + needle + spring + electronics combination product → device qualification (21 CFR 820, ISO 13485) overlaid on drug GMP.

13. Regulatory pathways

13.1 US (FDA)

  • CDER — small-molecule + most therapeutic biologics.
  • CBER — vaccines, blood + plasma, cell + gene therapy.
  • CDRH — devices + combination-product device constituent.
  • OCP / OCC — Office of Combination Products.

Pathways: IND → NDA / BLA (505(b)(1) full), 505(b)(2) hybrid (relies on prior approval data), ANDA (generic, demonstrate bioequivalence per FDA Bioequivalence Guidance), 351(k) biosimilar.

Accelerated designations:

  • Breakthrough Therapy (2012 FDASIA) — substantial improvement over existing.
  • Fast Track — serious condition + unmet need.
  • Accelerated Approval — surrogate endpoint; confirmatory required.
  • RMAT — Regenerative Medicine Advanced Therapy (21st Century Cures 2016) for cell + gene + tissue + combinations.
  • Priority Review — 6-mo target vs 10-mo standard.
  • Priority Review Voucher (PRV) — tropical disease, rare paediatric, medical countermeasure.

13.2 EU (EMA)

CTA (Clinical Trial Application under CTR EU 536/2014, fully transitioned 2025) → MAA (Marketing Authorisation Application) via:

  • Centralised procedure — mandatory for biotech, ATMP, orphan, new active substance (most modern launches).
  • Decentralised / Mutual Recognition — national first then expand.

Designations: PRIME (PRIority MEdicines), Orphan, Conditional MA, Accelerated Assessment.

13.3 Other regions

  • China NMPA — National Medical Products Administration (formerly CFDA); ICH-aligned since 2017 China-ICH accession.
  • Japan PMDA — Pharmaceuticals and Medical Devices Agency; Sakigake designation.
  • India CDSCO — Central Drugs Standard Control Organisation.
  • Health Canada — NOC (Notice of Compliance).
  • MHRA UK — post-Brexit ILAP (Innovative Licensing and Access Pathway).
  • TGA Australia — Provisional Approval.

14. Equipment + facility design

14.1 Cleanroom classification

ISO 14644-1 (revised 2015) particle count classification at 0.5 µm:

ISO classAt-rest particles ≥0.5 µm / m³EU GMP Annex 1 GradeTypical use
ISO 53520Grade AAseptic open product (under UDAF)
ISO 7352 000Grade B backgroundCleanroom around Grade A
ISO 83 520 000Grade CSolution prep, vial wash
ISO 8—Grade DComponent prep, gowning

HEPA H13 / H14 filtration (EN 1822); ULPA U15-U17 for ISO 4 / 3. Unidirectional airflow ≥0.36-0.54 m/s in Grade A.

14.2 Pharmaceutical waters

  • WFI (Water for Injection) — USP <1231>, EP. Endotoxin <0.25 EU/mL, conductivity <1.3 µS/cm at 25 °C.
    • Multi-effect distillation (MED) — traditional.
    • Vapour compression distillation (VCD).
    • Membrane / RO-EDI — permitted since USP <1231> 2017 revision + EP 0169 2017; lower energy. ISPE Baseline Guide Vol. 4 (Water + Steam, 2018 revision).
  • Purified Water (PW) — USP <1231>.
  • Clean Steam — generator (BWT Pharma + Biotech, Stilmas, Spirax-Sarco MECS).

14.3 Clean utilities

  • Compressed air — oil-free, dried + filtered to ISO 8573-1 Class 1.2.1 typically.
  • Pure N₂ + Ar — generator (PSA / membrane) + filtration; pharmaceutical grade per USP.
  • Process gas — CO₂ for bioreactor.

14.4 Flow + pressurisation

  • Personnel flow — gowning cascade D → C → B → A with airlocks.
  • Material flow — separated from personnel; pass-through hatches, isolators.
  • Pressure cascade — typically +10-15 Pa per grade boundary, positive into clean side. Containment (high-potency) inverts → negative inside.
  • Smoke studies — Annex 1 explicit requirement; visualise air sweep around critical zones.

14.5 High-potency API (HPAPI) containment

SafeBridge + AIHA banding: OEB / OEL bands:

BandOEL (TWA)
OEB 1>1000 µg/m³
OEB 2100-1000 µg/m³
OEB 310-100 µg/m³
OEB 41-10 µg/m³
OEB 5<1 µg/m³

Bands 4-5 require closed transfer (split-butterfly valves — GEA Hicoflex / ChargePoint PharmaSafe / Müller), isolators, LEV + HEPA exhaust, gowning + respiratory PPE. Oncology APIs (kinase inhibitors, ADC payloads — MMAE, DM1, calicheamicin, PBD dimers) almost universally OEB 5; ADC bioconjugation suites dedicated (Lonza Visp, Piramal Grangemouth, AGC Biologics).

15. Software, IT, data integrity

LayerFunctionVendors
MES (Mfg Execution)EBR (electronic batch record), recipe, dispatch, equipmentWerum PAS-X (Körber), Rockwell PharmaSuite, Siemens Opcenter Execution Pharma, AspenTech / Emerson Syncade, Honeywell Experion
LIMS (Lab Info Mgmt)Sample, test, result, COALabWare, STARLIMS (Abbott), LabVantage, Sapio Sciences
ELN (Electronic Lab Notebook)Discovery, dev, formulation notebookBenchling, IDBS E-WorkBook (Danaher), Dotmatics, PerkinElmer Signals, Revvity
ERPMaterials, finance, planningSAP S/4HANA Pharma, Oracle, Microsoft Dynamics
QMSCAPA, deviation, change ctrl, document, trainingVeeva Vault Quality, MasterControl, ETQ Reliance, Sparta Systems TrackWise
PI/historianTime-seriesOSIsoft PI (AVEVA), Aspen IP.21, Honeywell PHD, Wonderware Historian
MVDAMultivariate analysisSartorius SIMCA / SIMCA-online, Aspen ProMV, JMP, Camo
DMSDocument mgmtVeeva Vault QualityDocs, OpenText Documentum

Data integrity (DI) — global regulator-priority area since 2014-15 (Ranbaxy, Wockhardt, others). ALCOA+ principles; FDA 2018 + MHRA 2018 + WHO TRS 1019 Annex 5 (2019) guidance. 21 CFR Part 11 + EU Annex 11 govern computerised systems: audit trails, e-signatures, access control, validation per GAMP 5 (ISPE 2022 second edition).

16. Cost + economics (2024-26 indicative)

ModalityTypical CoG / price
Small-molecule API (commercial)2 000 / kg DS; ~$0.01-1 / dose oral
mAb DS3 000 / g (down from $5 000+ pre-2010 driven by titer + SUS)
Biosimilar mAb (US, list)3 000 / dose
mRNA vaccine~30 / dose CoG; price varies $20-130
CAR-T autologous475 k / dose (Yescarta 475 k DLBCL, Carvykti $465 k)
AAV gene therapy4.25 M / dose (Zolgensma 3.5 M, Elevidys 3.1 M)
CRISPR ex-vivo$2.2 M (Casgevy)
Semaglutide (US list, monthly)~1 350 (negotiated lower internationally; Wegovy ~970)
Tirzepatide (US list, monthly)~$1 060 (Zepbound 5 mg)
Insulin (US, monthly)$35 (Inflation Reduction Act capped 2023 Medicare; commercial varies)

CoG drivers for ATMPs: cell-bank + vector mfg (AAV vector ~50-100 k per CAR-T mfg slot), QC release (sterility + potency add ~$20-50 k/lot), cold-chain logistics.

17. Selection heuristics

NeedDefault platform
Oral solid tablet, large volume, mature routeBatch CDC with QbD + PAT, or fully continuous if NDA-stage
New molecule, complex synthesis, energetic intermediatesContinuous-flow + telescoping; pilot at Snapdragon / Lonza / Corning AFR
High-potency API (OEB 4-5; ADC, kinase inhibitor)Containment isolator + closed transfer + dedicated suite + LEV
mAb commercial, mature2000 L SUB fed-batch (4-6 trains) or stainless 12 000 L; intensified perfusion for cost-leadership
Biosimilar mAbSingle-use 2000 L fed-batch + accelerated tech transfer
mRNA / siRNA / ASOIVT or chem synthesis + microfluidic LNP; cold-chain critical
Autologous cell therapyLonza Cocoon / Miltenyi Prodigy automated suites + GMP cleanroom Grade B/A
Allogeneic cell therapyBioreactor (G-Rex, Xuri, Sartorius Ambr) + downstream + bank
AAV gene therapySuspension HEK293 + transient transfection + AVB / AVX affinity + AEX full/empty
Sterile injectable, small moleculeIsolator filling line + automated visual inspection (AVI) + AGV transport
Combination product (autoinjector pen for GLP-1, insulin)Cartridge fill + device qualification (ISO 13485 + 21 CFR 820) overlay
Lyophilised biologicVial fill + lyo + RABS or isolator; cycle development on small-scale lyo

18. Common pitfalls

  1. Data integrity violations — falsified records, shared logins, audit-trail disabled, untimed-then-backdated entries. Result: FDA Form 483, Warning Letter, Consent Decree, Import Alert. Remediation often $10-100 M and 1-3 years (cf. Ranbaxy 2008-13, Aurobindo + others 2019-23).
  2. Cleaning validation failures — cross-contamination of trace API between products on shared equipment; can trigger recall + Class I event (e.g. valsartan nitrosamine 2018 → industry-wide nitrosamine investigations).
  3. Tech-transfer batch failures during scale-up — heat-transfer surface-area/volume mismatch (kg/L), mixing-time differences (Zwietering), mass-transfer kLa drops in larger bioreactor → cell-density limit. Standard remediation: increase oxygen sparging, optimise impeller, geometric vs power-input scaling.
  4. Cell-line drift + genetic instability across MCB → WCB → production — productivity declines, glycosylation pattern shifts; requires production-cell-bank requalification.
  5. Cold-chain breaches — temperature excursions in transit (especially −80 °C mRNA); excursion deviation, stability impact assessment.
  6. Counterfeiting + supply-chain security — DSCSA US (fully enforced 2024-11) requires serialised aggregation through wholesaler; EU FMD (2019). Track-and-trace with GS1 SGTIN-198 barcode.
  7. Sterility failures + media-fill failures — Annex 1 2022 zero-tolerance; line shutdowns and regulatory consequence severe.
  8. Underestimating ATMP CoG — chain-of-identity / chain-of-custody, individualised QC release, vein-to-vein logistics often exceed planning by 2-3×.
  9. Single-source supplier risk (e.g. SmartLabel filter shortages 2020-22, glass vial pandemic shortage 2020-21, lipid PEG-DMG mRNA constraints 2020-22).

19. Cross-references

20. Citations + further reading

  • Vogel, H. + Todaro, C. (eds.). Fermentation and Biochemical Engineering Handbook (3rd ed., Elsevier / William Andrew, 2014).
  • Carstensen, J. T. + Rhodes, C. Drug Stability — Principles and Practices (4th ed., CRC Press, 2014).
  • Kim, S. + Patel, B. (eds.). Pharmaceutical Engineering (4th ed., ISPE, 2020).
  • Plotkin, S. + Buser, R. mRNA Vaccines (Springer, 2021).
  • Anastas, P. T. + Warner, J. C. Green Chemistry: Theory and Practice (Oxford, 1998).
  • Sheldon, R. A. “Organic synthesis — past, present and future.” Chem Ind (1992) 903-906 — E-factor.
  • Karikó, K. + Weissman, D. “Suppression of RNA recognition by Toll-like receptors.” Immunity 23, 165-175 (2005) — Nobel 2023.
  • DiMasi, J. A., Grabowski, H. G., Hansen, R. W. “Innovation in the pharmaceutical industry: New estimates of R&D costs.” J Health Econ 47, 20-33 (2016).
  • FDA. 21 CFR Parts 210, 211, 600, 610, 1271, 11, 820.
  • EU. EudraLex Volume 4 — GMP Guide + Annex 1 (2022 revision, in force 2023-08-25), Annexes 2, 11, 15, 16.
  • ICH. Q1A(R2), Q2(R2) 2023, Q3A-D, Q5A(R2) 2024, Q5B-E, Q6A-B, Q7, Q8(R2), Q9(R1) 2023, Q10, Q11, Q12, Q13 2022, Q14 2023.
  • ISPE. Baseline Guides Volumes 1-7 (Bulk Pharm; Oral Solid; Sterile; Water & Steam; Commissioning & Qualification; Biopharm; Risk-MaPP).
  • USP-NF. <1231> Water for Pharmaceutical Purposes; <797> Pharmaceutical Compounding — Sterile Preparations; <1207> Sterile Product Packaging — Integrity Evaluation.
  • WHO. TRS 1019 Annex 5 — Guideline on Data Integrity (2019).
  • PIC/S. PE 009 GMP Guide (current rev).
  • ICH. Q13 Continuous Manufacturing of Drug Substances and Drug Products (2022).
  • ISPE. GAMP 5 — A Risk-Based Approach to Compliant GxP Computerized Systems (2nd ed., 2022).
  • FDA. Guidance for Industry: PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (2004).
  • FDA. Guidance for Industry: Process Validation — General Principles and Practices (2011).
  • Tufts Center for the Study of Drug Development. Outlook 2024 — R&D cost benchmarking.
  • DiMasi, J. A. Briefing: Cost of Developing a New Drug (Tufts CSDD, 2020 update).

End of reference. Companion notes: chemical-process-fundamentals, biomechanics, quality-systems-iso9001.

Graph View